Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose dexamethasone to reduce postembolization syndrome after prostatic artery embolization
2020-000915-53Phase 4Terminated
- Sponsor
- Rigshospitalet
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in benign prostatic hyperplasia (BPH) comparing Dexamethasone arm with Placebo arm (2 arms). Primary endpoint: Reduction of postembolization syndrome (fever and pain). Started Mar 2020; status: terminated.
02
Drugs
dexamethasone
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on 2020-000915-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000915-53.